Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963)

Pasquale F. Innominato, Sylvie Giacchetti, Thierry Moreau, Rune Smaaland, Christian Focan, Georg A. Bjarnason, Carlo Garufi, Stefano Iacobelli, Marco Tampellini, Salvatore Tumolo, Carlos Carvalho, Abdoulaye Karaboué, Francis Lévi

Research output: Contribution to journalArticle

Abstract

Circadian clocks control cellular proliferation and drug metabolism over the 24h. However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the nontime-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963). The authors hypothesized that treatment near maximum tolerated dose could disrupt circadian clocks thus impairing the efficacy of chronoFLO4 but not of FOLFOX2. Patients with available data (N=556) were categorized into three subgroups according to the worst grade (G) of neutropenia experienced during treatment. Distinct multivariate models with time-dependent covariates were constructed for each treatment schedule. Neutropenia incidence (all grades) was 33% on chronoFLO4 and 61% on FOLFOX2 (p

Original languageEnglish
Pages (from-to)586-600
Number of pages15
JournalChronobiology International
Volume28
Issue number7
DOIs
Publication statusPublished - Aug 2011

Fingerprint

oxaliplatin
Leucovorin
Neutropenia
Fluorouracil
Colorectal Neoplasms
Appointments and Schedules
Circadian Clocks
Survival
Maximum Tolerated Dose
Therapeutics
Cell Proliferation
Drug Therapy
Incidence
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Chronotherapy
  • Circadian
  • Colorectal cancer
  • Neutropenia
  • Prognostic factor

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). / Innominato, Pasquale F.; Giacchetti, Sylvie; Moreau, Thierry; Smaaland, Rune; Focan, Christian; Bjarnason, Georg A.; Garufi, Carlo; Iacobelli, Stefano; Tampellini, Marco; Tumolo, Salvatore; Carvalho, Carlos; Karaboué, Abdoulaye; Lévi, Francis.

In: Chronobiology International, Vol. 28, No. 7, 08.2011, p. 586-600.

Research output: Contribution to journalArticle

Innominato, PF, Giacchetti, S, Moreau, T, Smaaland, R, Focan, C, Bjarnason, GA, Garufi, C, Iacobelli, S, Tampellini, M, Tumolo, S, Carvalho, C, Karaboué, A & Lévi, F 2011, 'Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963)', Chronobiology International, vol. 28, no. 7, pp. 586-600. https://doi.org/10.3109/07420528.2011.597532
Innominato, Pasquale F. ; Giacchetti, Sylvie ; Moreau, Thierry ; Smaaland, Rune ; Focan, Christian ; Bjarnason, Georg A. ; Garufi, Carlo ; Iacobelli, Stefano ; Tampellini, Marco ; Tumolo, Salvatore ; Carvalho, Carlos ; Karaboué, Abdoulaye ; Lévi, Francis. / Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). In: Chronobiology International. 2011 ; Vol. 28, No. 7. pp. 586-600.
@article{a3ea053f3361468d842cad8de7b0f341,
title = "Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963)",
abstract = "Circadian clocks control cellular proliferation and drug metabolism over the 24h. However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the nontime-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963). The authors hypothesized that treatment near maximum tolerated dose could disrupt circadian clocks thus impairing the efficacy of chronoFLO4 but not of FOLFOX2. Patients with available data (N=556) were categorized into three subgroups according to the worst grade (G) of neutropenia experienced during treatment. Distinct multivariate models with time-dependent covariates were constructed for each treatment schedule. Neutropenia incidence (all grades) was 33{\%} on chronoFLO4 and 61{\%} on FOLFOX2 (p",
keywords = "Chemotherapy, Chronotherapy, Circadian, Colorectal cancer, Neutropenia, Prognostic factor",
author = "Innominato, {Pasquale F.} and Sylvie Giacchetti and Thierry Moreau and Rune Smaaland and Christian Focan and Bjarnason, {Georg A.} and Carlo Garufi and Stefano Iacobelli and Marco Tampellini and Salvatore Tumolo and Carlos Carvalho and Abdoulaye Karabou{\'e} and Francis L{\'e}vi",
year = "2011",
month = "8",
doi = "10.3109/07420528.2011.597532",
language = "English",
volume = "28",
pages = "586--600",
journal = "Chronobiology International",
issn = "0742-0528",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963)

AU - Innominato, Pasquale F.

AU - Giacchetti, Sylvie

AU - Moreau, Thierry

AU - Smaaland, Rune

AU - Focan, Christian

AU - Bjarnason, Georg A.

AU - Garufi, Carlo

AU - Iacobelli, Stefano

AU - Tampellini, Marco

AU - Tumolo, Salvatore

AU - Carvalho, Carlos

AU - Karaboué, Abdoulaye

AU - Lévi, Francis

PY - 2011/8

Y1 - 2011/8

N2 - Circadian clocks control cellular proliferation and drug metabolism over the 24h. However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the nontime-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963). The authors hypothesized that treatment near maximum tolerated dose could disrupt circadian clocks thus impairing the efficacy of chronoFLO4 but not of FOLFOX2. Patients with available data (N=556) were categorized into three subgroups according to the worst grade (G) of neutropenia experienced during treatment. Distinct multivariate models with time-dependent covariates were constructed for each treatment schedule. Neutropenia incidence (all grades) was 33% on chronoFLO4 and 61% on FOLFOX2 (p

AB - Circadian clocks control cellular proliferation and drug metabolism over the 24h. However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the nontime-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963). The authors hypothesized that treatment near maximum tolerated dose could disrupt circadian clocks thus impairing the efficacy of chronoFLO4 but not of FOLFOX2. Patients with available data (N=556) were categorized into three subgroups according to the worst grade (G) of neutropenia experienced during treatment. Distinct multivariate models with time-dependent covariates were constructed for each treatment schedule. Neutropenia incidence (all grades) was 33% on chronoFLO4 and 61% on FOLFOX2 (p

KW - Chemotherapy

KW - Chronotherapy

KW - Circadian

KW - Colorectal cancer

KW - Neutropenia

KW - Prognostic factor

UR - http://www.scopus.com/inward/record.url?scp=80052071637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052071637&partnerID=8YFLogxK

U2 - 10.3109/07420528.2011.597532

DO - 10.3109/07420528.2011.597532

M3 - Article

C2 - 21859417

AN - SCOPUS:80052071637

VL - 28

SP - 586

EP - 600

JO - Chronobiology International

JF - Chronobiology International

SN - 0742-0528

IS - 7

ER -